United Kingdom
Search    
Include All CSL Behring Country Sites
For Healthcare Professionals
CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products including:
null Coagulation therapies
For rapid warfarin reversal, von Willebrand disease, haemophilia and congenital fibrinogen deficiency
null Immunology therapies
For hereditary angioedema, immune deficiency disorders, and haemolytic disease of the newborn
Resource centre for healthcare professionals
For Patients
Rapid warfarin reversal
Von Willebrand Disease
Haemophilia
Congenital Fibrinogen Deficiency
Immune Deficiency Disorders
Hereditary Angioedema
Haemolytic Disease of the Newborn
News
4-Apr-2013
CSL Behring announced today that the European Commission has ...
3-Apr-2013
As part of its ongoing commitment to the global coagulation ...
21-Jan-2013
CSL Behring has announced that the first patient has been ...
14-Jan-2013
CSL Behring Seeks Proposals for the Third Annual Interlaken ...
19-Dec-2012
Phase II Study Indicates that Fibrinogen Concentrate Given as a ...